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Drug administration and scheduling
Combretastatin-A4 3-O phosphate (CA-4-P) was supplied by Toroma Organics (Saarbruecken, Germany) and stored at 4°C. The formulation was reconstituted to achieve a concentration of 30 mg/mL in sodium chloride 0.9% and was administered as a single dose of 50 mg/kg or 100 mg/kg body weight as indicated via tail vein injection.
Control groups received sodium chloride 0.9%. SU11248/sunitinib malate was supplied by Pfizer and stored at room temperature. The formulation was re-suspended in carboxy methylcellulose sodium (0.5% wt/vol), NaCl (1.8% wt/vol), Tween 80 (0.4% wt/vol), and isopropanol (0.9% wt/vol) to achieve a concentration of 12 mg/mL. Sunitinib was administered orally at 40 mg/kg (100µL) once a day, in different schedules. Control groups received methylcellulose at the same volume and schedule. DC101, a rat monoclonal antibody specific for mouse VEGFR-2/flk-1, was administered intraperitoneal (i.p.) at a concentration of 800µg/mouse. Treatment was given as CA-4-P, sunitinib, or DC101, alone or in combination with administration of sunitinib or DC101 24 hours prior to CA-4-P injection or prior to the second CEP burst.
Evaluation of CEC and CEP levels by flow cytometry
Five-color flow cytometry assays were established to enumerate CECs and CEPs in mouse peripheral whole blood. Methodological characteristics included: -1) sampling of an important volume of blood (≥ 250 µl), 2) accumulation of a large number of events (at least 150,000 mononuclear cells per sample) to ensure statistical analysis, and 3) use of specific fluorescence minus-one (FMO) controls to measure accurately background noise. CECs were measured in whole blood after immunofluorescent staining with the following rat anti-mouse monoclonal antibodies: CD31-FITC, CD45-PerCP, Flk-1 (VEGFR2)-PE, MECA-32 biotin and streptavidin-APC (all from BD Pharmingen) ( Supplementary Fig. S1 ). Antibody batches were titrated rigorously to determine optimal dosage. MECA-32 biotin and Flk-1-PE antibodies were titrated using blood samples presenting elevated levels of CECs obtained from colchicine-treated animals (data not shown). CEPs were measured in whole blood using the following monoclonal antibodies:
CD45-PerCP, CD117-APC, Sca-1-FITC and Flk-1-PE (all from BD Pharmingen) (4-6).
An isotypic control tube included fluorochrome-conjugated rat anti-mouse isotypic controls. For CEC and CEP identification strategies, fluorescence-minus-one (FMO) control tubes for each fluorochrome were performed in 250µL of whole blood to measure background noise and to adjust the gates precisely according to recommended procedures ) populations. For this, CEPs measured according to our strategy (n=10 mice) were compared to CEPs identified using a strategy with a lineage-"dump" channel (including CD2, CD3, CD4, CD11b, CD14, CD19, CD20 and F4/80) (n=10 mice). As shown in Supplementary Fig. S3 Fig. S4 ).
Measurement of pro-angiogenic factor levels in serum and bone marrow samples
Murine serum levels of VEGF, matrix metallopeptidase 9 (MMP9), stromalderived factor-1 (SDF-1) and granulocyte colony-stimulating factor (G-CSF) were determined using commercially available mouse ELISA kits (R&D Systems, Mineapolis, MN). Because manufacturers recommend using serum for both G-CSF and SDF-1 dosages, all protein dosages were performed in serum samples instead of plasma. Blood samples were drawn in dry tubes and centrifuged, after which serum was aliquoted, frozen and stored at -70°C until assayed. SDF-1 levels were also determined in the supernatant of BM samples. For this, femurs and tibias were taken immediately from animals sacrificed at indicated times, and the BM was directly flushed into 100 µl RPMI medium (Gibco, Paisley, UK) supplemented with 10% fetal calf serum (Gibco) using a syringe and 21-gauge needle. The BM cell suspension was centrifuged and the supernatant was immediately frozen and stored at -80°C until assayed. Optical density 7 values were considered significant if found to be at least twice as high as background noise.
Image acquisition and analysis
Digital images of whole histological tumor sections were acquired using a Zeiss Axiophot microscope (magnification 25X) and recorded using a Nikon SuperCoolscan Mice were treated with CA-4-P, DC101, or sunitinib according to the design presented in Figure 5B and C. Three days after the 4 hour or 72 hour CEP peak, tumors were removed (at day 3 and day 6, respectively) and cryosections were prepared for the assessment of including prostate cancer (PC3 (n=53), IGR CAP (n=48), and MDA PCA 2b (n=20)), lung cancer (A549 (n=49) and H69 (n=14)) and neuroblastoma (N91 (n=15)).
Measurements began when tumors achieved a volume of at least 300 mm Representative frames can be seen in Figure 6B .
Supplementary Movie M2
Myeloid cells are located perivascularly. Immunohistochemistry staining for CD31 (red), 
